Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. News/
  3. Health & wellness/
  4. By the numbers: Who gets lung cancer?
A female doctor in a lab coat pointing to an xray of lungs on a tablet while explaining something to two seated patients.

By the numbers: Who gets lung cancer?

Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Learn how Johnson & Johnson is dedicated to improving outcomes by integrating the company’s MedTech and Innovative Medicine expertise.

Lung cancer is—by far—the leading cause of all cancer deaths across the globe, with 1.8 million people dying from the disease each year. Part of the reason has to do with the fact that early symptoms mimic common respiratory illnesses, so people with lung cancer often aren’t diagnosed until their cancer has reached an advanced stage.

Also at play? The “typical” patient is no longer so typical. Smokers, in other words, aren’t the only people at risk. Anyone who has a family history of the disease or is exposed to secondhand smoke and air pollution is also vulnerable.

But advances in early detection and breakthrough treatments are helping improve lung cancer outcomes. For one, the American Cancer Society recently updated its screening guidelines, recommending that people between the ages of 50 and 80 who smoke or formerly smoked 20 or more packs a year get screened annually.

And when it comes to developing innovative treatments, Interventional Oncology at Johnson & Johnson is focused on integrating the company’s MedTech and Innovative Medicine expertise to deliver therapies directly into lung tumors via minimally invasive procedures.

Here’s a look at the prevalence, diagnosis and mortality rates of lung cancer worldwide—and how Johnson & Johnson is playing a role in improving the lives of patients.

Infographic of who gets lung cancer on a red and white background

More ways Johnson & Johnson is working to fight lung cancer

See how researchers are developing preventive approaches for early detection, creating new therapies and more.

More from Johnson & Johnson

How Johnson & Johnson is advancing the fight against Alzheimer’s disease

After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.

Is this the end of one-size-fits-all treatments for depression?

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.

What is inflammation?

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to inflammatory bowel disease, psoriasis and rheumatoid arthritis, among other immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.